Quantum Genomics Announces Issuance of New Patents Protecting its QGC606 Product
Quantum Genomics (Euronext Growth: ALQGC, OTCQX: QNNTF),
biopharmaceutical company specializing in the development of a new class of drugs that directly target the brain to treat resistant hypertension and heart failure, announces the strengthening of industrial property around aminopeptidase A inhibitors with the delivery of new patents protecting its second drug candidate, QGC606.
The United States Patent and Trademark Office (USPTO) has transmitted its agreement to grant a patent resulting from application No. US 17/437,862 filed on September 10, 2021. The Australian Patent Office has validated the grant of patent AU2020235216 without modification of the application filed on August 17, 2021.
These two new patents protect in the United States and Australia until March 2040, a new chemical series of cerebral aminopeptidase A inhibitors and more particularly the drug candidate QGC606, as well as any pharmaceutical composition comprising one of these inhibitors as active principle, for therapeutic use in the treatment of cardiovascular pathologies.
Fabrice Balavoine, Research & Development Director of Quantum Genomics, comments: “These new patents are further proof of our know-how and our expertise in the design and development of therapeutic innovations. The examination of these applications was particularly fast and was not the subject of any major objection, which makes us particularly confident that we will soon obtain patents with similar claims in the rest of the world and thus guarantee solid industrial protection. of QGC606 and its therapeutic use. »
Jean-Philippe Milon, CEO of Quantum Genomics, adds: “The issuance of these new patents is excellent news because these patents further consolidate the industrial property around our technological platform. As we actively pursue the clinical development of firibastat, our product “
first-in-class »
it was important to develop and protect a second generation of cerebral aminopeptidase A inhibitors to meet the standards of the pharmaceutical industry as well as the expectations of large
laboratories”.
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the mechanism of inhibition of brain Aminopeptidase A (Brain Aminopeptidase A Inhibition or BAPAI). The only company in the world to pursue this innovative approach directly targeting the brain, it relies on more than twenty years of research from the University of Paris-Descartes and the INSERM/CNRS laboratory directed by Dr. Catherine Llorens-Cortès at France secondary school. Quantum Genomics thus aims to develop innovative treatments for complicated or even resistant arterial hypertension (about 30% of patients are poorly controlled or fail treatment), and heart failure (one out of two diagnosed patients dies within five years).
Based in Paris, the company is listed on the Euronext Growth market in Paris (FR0011648971 – ALQGC) and registered on the American market OTCQX (symbol: QNNTF).
More information on www.quantum-genomics.com, our Twitter and Linkedin accounts
contacts
|
Quantum Genomics | |
|
Communication building (EUROPE) | |
Financial communication and media | |
|
LifeSci (US) | |
Mike Tattory |
This post has the “? Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
yZ1yYJtpY5yXyHJtlMptbJOVmGmTkmGUZmSWmWZoZpyYbZuVnJdlaJaWZnBknGZp
– To check this key:
https://www.security-master-key.com.
Regulated information:
Inside information:
– Other press releases
Full and original press release in PDF format:
https://www.actusnews.com/news/73713-cp-brevets-qgc606_fr.pdf
© Copyright Actusnews Wire
Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com